Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C
Retinopathy is associated with the use of interferon and ribavirin for the treatment of chronic hepatitis C. Common ocular complications include cotton wool spots, retinal hemorrhages, and macular edema. A 53-year-old black man with a history of drug and alcohol abuse was admitted to the Department...
Gespeichert in:
| Veröffentlicht in: | Optometry (Saint Louis, Mo.) Mo.), 2010-11, Vol.81 (11), p.580-586 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 586 |
|---|---|
| container_issue | 11 |
| container_start_page | 580 |
| container_title | Optometry (Saint Louis, Mo.) |
| container_volume | 81 |
| creator | Adams, Shelly Ostermeier, Mark |
| description | Retinopathy is associated with the use of interferon and ribavirin for the treatment of chronic hepatitis C. Common ocular complications include cotton wool spots, retinal hemorrhages, and macular edema.
A 53-year-old black man with a history of drug and alcohol abuse was admitted to the Department of Veterans Affairs clinic for substance abuse treatment. Results of a liver biopsy showed chronic hepatitis C, and treatment with interferon and ribavirin was initiated. A comprehensive eye examination was performed just before the initiation of treatment, and the patient was then periodically monitored for the presence of retinopathy. No retinopathy was found at the initial visit or at his 1-month or 2-month follow-up examinations. His 4-month retinal evaluation found cotton wool spots in both eyes and retinal hemorrhages in the left eye. The retinopathy persisted for several months but resolved in both eyes before his treatment was discontinued. Throughout his treatment period there were no visual complaints or visual acuity changes.
Although this patient was visually asymptomatic, and his retinopathy resolved during treatment, we chose to monitor the patient monthly during treatment because of the risk of serious (although rare) ocular complications. |
| doi_str_mv | 10.1016/j.optm.2010.04.094 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_762031154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1529183910003155</els_id><sourcerecordid>762031154</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-323f0a010e5af90916bd98e1e669502af927ba593dbbfe836efd167c4c402e053</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMoVqsv4EKyczU1l0k6A26keIOCILqOmcwZm9KZjEla6dubsdWlq3PhOz-cD6ELSiaUUHm9nLg-thNG0oLkE1LmB-iEClFkVLDp4dCzMqMFL0foNIQlIbyQXByjESNSCFbwE_T-AtF2rtdxscU6BGesjlDjLxsXuIeP7epntF0E34B3HdZdjb2t9MZ62-HoQccWuogb57FZJMIavIAUaKMNeHaGjhq9CnC-r2P0dn_3OnvM5s8PT7PbeWa4EDHjjDdEp09A6KYkJZVVXRZAQcpSEJZ2bFppUfK6qhoouISmpnJqcpMTBkTwMbra5fbefa4hRNXaYGC10h24dVBTyQinVOSJZDvSeBeCh0b13rbabxUlahCrlmoQqwaxiuQqiU1Hl_v4ddVC_XfyazIBNzsA0pMbC14FY6EzUFsPJqra2f_yvwGF8ouk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>762031154</pqid></control><display><type>article</type><title>Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Adams, Shelly ; Ostermeier, Mark</creator><creatorcontrib>Adams, Shelly ; Ostermeier, Mark</creatorcontrib><description>Retinopathy is associated with the use of interferon and ribavirin for the treatment of chronic hepatitis C. Common ocular complications include cotton wool spots, retinal hemorrhages, and macular edema.
A 53-year-old black man with a history of drug and alcohol abuse was admitted to the Department of Veterans Affairs clinic for substance abuse treatment. Results of a liver biopsy showed chronic hepatitis C, and treatment with interferon and ribavirin was initiated. A comprehensive eye examination was performed just before the initiation of treatment, and the patient was then periodically monitored for the presence of retinopathy. No retinopathy was found at the initial visit or at his 1-month or 2-month follow-up examinations. His 4-month retinal evaluation found cotton wool spots in both eyes and retinal hemorrhages in the left eye. The retinopathy persisted for several months but resolved in both eyes before his treatment was discontinued. Throughout his treatment period there were no visual complaints or visual acuity changes.
Although this patient was visually asymptomatic, and his retinopathy resolved during treatment, we chose to monitor the patient monthly during treatment because of the risk of serious (although rare) ocular complications.</description><identifier>ISSN: 1529-1839</identifier><identifier>EISSN: 1558-1527</identifier><identifier>DOI: 10.1016/j.optm.2010.04.094</identifier><identifier>PMID: 20655283</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Drug Administration Schedule ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Humans ; Injections, Subcutaneous ; Interferon-alpha - administration & dosage ; Interferon-alpha - adverse effects ; Male ; Middle Aged ; Pegylated interferon ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - adverse effects ; Recombinant Proteins ; Remission, Spontaneous ; Retinal Hemorrhage - chemically induced ; Retinal Hemorrhage - physiopathology ; Retinopathy ; Ribavirin ; Ribavirin - administration & dosage ; Ribavirin - adverse effects</subject><ispartof>Optometry (Saint Louis, Mo.), 2010-11, Vol.81 (11), p.580-586</ispartof><rights>2010</rights><rights>Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c355t-323f0a010e5af90916bd98e1e669502af927ba593dbbfe836efd167c4c402e053</citedby><cites>FETCH-LOGICAL-c355t-323f0a010e5af90916bd98e1e669502af927ba593dbbfe836efd167c4c402e053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20655283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adams, Shelly</creatorcontrib><creatorcontrib>Ostermeier, Mark</creatorcontrib><title>Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C</title><title>Optometry (Saint Louis, Mo.)</title><addtitle>Optometry</addtitle><description>Retinopathy is associated with the use of interferon and ribavirin for the treatment of chronic hepatitis C. Common ocular complications include cotton wool spots, retinal hemorrhages, and macular edema.
A 53-year-old black man with a history of drug and alcohol abuse was admitted to the Department of Veterans Affairs clinic for substance abuse treatment. Results of a liver biopsy showed chronic hepatitis C, and treatment with interferon and ribavirin was initiated. A comprehensive eye examination was performed just before the initiation of treatment, and the patient was then periodically monitored for the presence of retinopathy. No retinopathy was found at the initial visit or at his 1-month or 2-month follow-up examinations. His 4-month retinal evaluation found cotton wool spots in both eyes and retinal hemorrhages in the left eye. The retinopathy persisted for several months but resolved in both eyes before his treatment was discontinued. Throughout his treatment period there were no visual complaints or visual acuity changes.
Although this patient was visually asymptomatic, and his retinopathy resolved during treatment, we chose to monitor the patient monthly during treatment because of the risk of serious (although rare) ocular complications.</description><subject>Administration, Oral</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Drug Administration Schedule</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Interferon-alpha - adverse effects</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pegylated interferon</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Recombinant Proteins</subject><subject>Remission, Spontaneous</subject><subject>Retinal Hemorrhage - chemically induced</subject><subject>Retinal Hemorrhage - physiopathology</subject><subject>Retinopathy</subject><subject>Ribavirin</subject><subject>Ribavirin - administration & dosage</subject><subject>Ribavirin - adverse effects</subject><issn>1529-1839</issn><issn>1558-1527</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMoVqsv4EKyczU1l0k6A26keIOCILqOmcwZm9KZjEla6dubsdWlq3PhOz-cD6ELSiaUUHm9nLg-thNG0oLkE1LmB-iEClFkVLDp4dCzMqMFL0foNIQlIbyQXByjESNSCFbwE_T-AtF2rtdxscU6BGesjlDjLxsXuIeP7epntF0E34B3HdZdjb2t9MZ62-HoQccWuogb57FZJMIavIAUaKMNeHaGjhq9CnC-r2P0dn_3OnvM5s8PT7PbeWa4EDHjjDdEp09A6KYkJZVVXRZAQcpSEJZ2bFppUfK6qhoouISmpnJqcpMTBkTwMbra5fbefa4hRNXaYGC10h24dVBTyQinVOSJZDvSeBeCh0b13rbabxUlahCrlmoQqwaxiuQqiU1Hl_v4ddVC_XfyazIBNzsA0pMbC14FY6EzUFsPJqra2f_yvwGF8ouk</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Adams, Shelly</creator><creator>Ostermeier, Mark</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20101101</creationdate><title>Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C</title><author>Adams, Shelly ; Ostermeier, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-323f0a010e5af90916bd98e1e669502af927ba593dbbfe836efd167c4c402e053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Administration, Oral</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Drug Administration Schedule</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Interferon-alpha - adverse effects</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pegylated interferon</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Recombinant Proteins</topic><topic>Remission, Spontaneous</topic><topic>Retinal Hemorrhage - chemically induced</topic><topic>Retinal Hemorrhage - physiopathology</topic><topic>Retinopathy</topic><topic>Ribavirin</topic><topic>Ribavirin - administration & dosage</topic><topic>Ribavirin - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adams, Shelly</creatorcontrib><creatorcontrib>Ostermeier, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Optometry (Saint Louis, Mo.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adams, Shelly</au><au>Ostermeier, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C</atitle><jtitle>Optometry (Saint Louis, Mo.)</jtitle><addtitle>Optometry</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>81</volume><issue>11</issue><spage>580</spage><epage>586</epage><pages>580-586</pages><issn>1529-1839</issn><eissn>1558-1527</eissn><abstract>Retinopathy is associated with the use of interferon and ribavirin for the treatment of chronic hepatitis C. Common ocular complications include cotton wool spots, retinal hemorrhages, and macular edema.
A 53-year-old black man with a history of drug and alcohol abuse was admitted to the Department of Veterans Affairs clinic for substance abuse treatment. Results of a liver biopsy showed chronic hepatitis C, and treatment with interferon and ribavirin was initiated. A comprehensive eye examination was performed just before the initiation of treatment, and the patient was then periodically monitored for the presence of retinopathy. No retinopathy was found at the initial visit or at his 1-month or 2-month follow-up examinations. His 4-month retinal evaluation found cotton wool spots in both eyes and retinal hemorrhages in the left eye. The retinopathy persisted for several months but resolved in both eyes before his treatment was discontinued. Throughout his treatment period there were no visual complaints or visual acuity changes.
Although this patient was visually asymptomatic, and his retinopathy resolved during treatment, we chose to monitor the patient monthly during treatment because of the risk of serious (although rare) ocular complications.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>20655283</pmid><doi>10.1016/j.optm.2010.04.094</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1529-1839 |
| ispartof | Optometry (Saint Louis, Mo.), 2010-11, Vol.81 (11), p.580-586 |
| issn | 1529-1839 1558-1527 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_762031154 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Administration, Oral Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Drug Administration Schedule Hepatitis C Hepatitis C, Chronic - drug therapy Humans Injections, Subcutaneous Interferon-alpha - administration & dosage Interferon-alpha - adverse effects Male Middle Aged Pegylated interferon Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Recombinant Proteins Remission, Spontaneous Retinal Hemorrhage - chemically induced Retinal Hemorrhage - physiopathology Retinopathy Ribavirin Ribavirin - administration & dosage Ribavirin - adverse effects |
| title | Retinopathy associated with pegylated interferon and ribavirin treatment for chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T14%3A11%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Retinopathy%20associated%20with%20pegylated%20interferon%20and%20ribavirin%20treatment%20for%20chronic%20hepatitis%20C&rft.jtitle=Optometry%20(Saint%20Louis,%20Mo.)&rft.au=Adams,%20Shelly&rft.date=2010-11-01&rft.volume=81&rft.issue=11&rft.spage=580&rft.epage=586&rft.pages=580-586&rft.issn=1529-1839&rft.eissn=1558-1527&rft_id=info:doi/10.1016/j.optm.2010.04.094&rft_dat=%3Cproquest_cross%3E762031154%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=762031154&rft_id=info:pmid/20655283&rft_els_id=S1529183910003155&rfr_iscdi=true |